Feb 25, 2026 04:02PM

Jan 8, 2026 08:03AM

Jan 8, 2026 08:00AM

Dec 21, 2025 08:00PM

Nov 5, 2025 04:02PM

Oct 27, 2025 08:01AM

Oct 27, 2025 08:00AM Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

Oct 17, 2025 05:16AM

Oct 16, 2025 08:00PM

Aug 6, 2025 04:02PM

Jul 23, 2025 08:00AM

Jul 23, 2025 08:00AM

Jun 30, 2025 08:07AM

Jun 30, 2025 08:00AM Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

Jun 24, 2025 07:01AM

Jun 24, 2025 07:00AM

Jun 23, 2025 09:01AM

Jun 23, 2025 09:00AM

Apr 9, 2025 05:00AM

Feb 26, 2025 04:02PM

Jan 4, 2025 04:00PM 2025 Biopharma sector outlook

Jan 2, 2025 04:00PM

Jan 2, 2025 12:51PM

Aug 7, 2024 04:05PM

Jul 15, 2024 08:53AM

May 9, 2022 04:02PM

Aug 11, 2021 04:01PM

Mar 2, 2021 04:05PM Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress

Mar 2, 2021 04:05PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All